Burden, risk factors, and management of neutropenic fever among solid cancer patients in Ethiopia

Samuel AgegneWondm¹, Ephrem Mebratu Dagnew¹, Sumeya Tadesse Abegaz², Mekdes Kiflu¹ and Bekalu Kebede¹

Abstract
Objectives: Although neutropenic fever is one of the most well-known oncologic emergencies and the common causes of death, a few studies have been conducted in resource-limited countries, particularly in Ethiopia. This study aimed to assess the burden, risk factors, and management of neutropenic fever among solid cancer patients in Ethiopia.

Methods: A hospital-based retrospective follow-up study was conducted from January 2017 to February 2021. Data were collected from patient’s medical charts using a structured data abstraction format and analyzed using STATA version 14.2. Logistic regression analyses were used to identify independent predictors of neutropenic fever, and a \( p \)-value of \( < 0.05 \) was considered statistically significant.

Results: A total of 416 patients were included, with a mean age of 51 ± 14 years. The cumulative incidence of neutropenic fever was 13%. Advanced age, low baseline white blood cell, prolonged duration of neutropenia, and presence of two or more comorbidities were factors significantly associated with neutropenic fever (\( p < 0.05 \)). Among patients who need primary prophylaxis, 68% of patients did not get appropriate primary prophylaxis, and 30%, 71%, and 93% of prescribed anti-bacterial, anti-fungal, and anti-viral agents were inappropriate according to Infectious Disease Society of America Guideline, respectively.

Conclusion: Neutropenic fever was common among solid cancer patients and it is multifactorial. The rate of guideline adherence during prophylaxis and treatment of neutropenic fever was poor. Health care professionals should be aware of these risk factors, and greater effort is needed to reduce the risk of neutropenic fever.

Keywords
Burden, neutropenic fever, solid cancer, treatment, guideline adherence, University of Gondar, Ethiopia

Date received: 26 November 2021; accepted: 14 April 2022

Introduction
Cancer is a group of diseases that results from uncontrolled growth and reproduction of body cells.¹ It is one of the most common causes of morbidity and mortality in Ethiopia.² A survey conducted in 182 countries reported that there were 7.6 million cancer-related deaths in 2008, of which 63% of death occurred in developing countries.³ In 2018, there were 18.1 million new cases of cancer and 9.6 million associated deaths in the world.⁴ According to the National Ministry of Health, Ethiopia, there are 60,960 new cases, and 5.8% of total national death every year in Ethiopia is due to cancer.¹

Neutrophils are a part of the phagocyte system and the first cellular component for inflammatory response and innate immunity.⁵ Neutropenic fever (NF) is the most well-known oncologic emergency and life-threatening medical condition. On average, 2%–21% among hospitalized cancer patients in the United States died because of NF.⁶ Cancer patients are at high risk of infection because of different reasons; breakdown of normal skin and mucosal barriers, reduced and altered

¹Clinical Pharmacy Unit, Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia
²Clinical Pharmacy Department, School of Pharmacy, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia

Corresponding author: Bekalu Kebede, Clinical Pharmacy Unit, Department of Pharmacy, College of Health Sciences, Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia.
Email: bekalukebede19@gmail.com
immunoglobulin, bone marrow abnormality, and neutropenia secondary to chemotherapy are common risk factors. In the absence of prophylaxis use, between 48% and 60% of neutropenia patients become febrile, and around 16% to 20% of them have bacteremia.\(^7\) History of prior NF, significant metastasis disease, absence of antibiotics prophylaxis measure or granulocyte colony stimulating factor (G-CSF), cardiovascular disease, poor performance status, poor performance status, and cardiovascular disease are significantly associated with a high mortality rate.\(^8\)

NF is a common and life-threatening complication of chemotherapy treatment in patients with solid cancer patients, which required urgent diagnosis and interventions. Empirical antibiotics therapy is standard practice in the treatment of NF.\(^9,10\) However, there is a significant debate about the selection of initial antibiotic regimens.\(^3\) The initial regimen in seriously ill patients should cover both gram-positive and gram-negative pathogens and should be administered intravenously.\(^11–13\) However, vancomycin (or other agents active against aerobic gram-positive cocci) is not recommended as a standard part of the initial antibiotic regimen for fever and neutropenia (A–I). These agents should be considered for specific clinical indications, including suspected catheter-related infection, skin or soft-tissue infection, pneumonia, or hemodynamic instability.\(^14\) Administrations of antibiotics reduce mortality, shorten the length of hospital stay, and increase the quality of life.\(^7,11\) However, these are not evidenced in developing countries including Ethiopia because of low screening practices for different cancers, lack of antibiotic sensitivity tests, and inappropriate use of antibiotics. Despite the presence of frustrating reports on the overuse of antibiotics in general medical use, few studies have been conducted on the burden and management practice of NF in Ethiopia. Therefore, the objective of this study was to assess the burden, risk factors, and management of NF among solid organ cancer patients in Ethiopia.

**Methods**

**Study design, period, and area**

A hospital-based retrospective follow-up study was conducted among adult solid cancer patients attending between 1 January 2017 and 30 February 2021 at the oncology ward of the University of Gondar Comprehensive and Specialized Hospital (UOGCSH).

**Study population**

Patients with a confirmed diagnosis of a malignant solid tumor with age ≥18 years, who were on cancer chemotherapy, and who had a normal baseline absolute neutrophil count were included in this study. We exclude patients who had a history of neutropenia, prior exposure to chemotherapy, and incomplete medical and laboratory records. Because of this group of patients, it was difficult to differentiate the new case of neutropenia from the older existing case.

**Sample size determination and sampling techniques**

Cochran single proportion formula for a categorical variable was used to calculate the required sample size for this study. As per the Authors’ knowledge, no study was found in Ethiopia on this area. Therefore, 50% of the incident rate was used in the sample size calculation. Using standard normal distribution (\(Z=1.96\)) with a confidence interval (CI) of 95% and 0.05 marginal error, the minimum sample size required for this study was 384. After adding a 10% non-response rate, the calculated sample size was 423. Finally, 416 participants were included in the final analysis because 7 participants had incomplete data that were identified during data entry. A systematic random sampling technique was used and the proportional allocation was presented (Figure 1). The population from January 2017 to February 2021 was 953 and the sample size calculated was 423. \(K=N/n;\) thus, \(K=2\); \(25=2\). We took the sample of every two patients until the sample size was reached.

**Outcome measure**

The primary outcome of this study was an incidence of NF. The proportion of guideline adherence during prophylaxis use and management of NF was the secondary outcome of this study.

**Data collection and tool**

A structured, pretested data abstraction format prepared by reviewing different kinds of literature was used to collect all necessary data from patients’ medical charts. The data abstraction format is composed of detailed information on patients’ characteristics, including sex, age, residency, occupation, body mass index (BMI), body surface area (BSA), and clinical data, including diagnosis/assessments, type of malignancy, types chemotherapy agent, number of medications, number of cycles, comorbidities, absolute neutrophil counts, body temperature, selected empiric therapy for NF, including the name of the drug(s), chemotherapy delay, and duration of therapy. The National Comprehensive Cancer Network (NCCN) guideline and Infectious Diseases Society of America (IDSA) guideline were used as standard guidelines to evaluate appropriate indications of prophylaxis and empiric antibiotic for NF, respectively. Risk classification was performed using the Multinational Association for Supportive Care in Cancer (MASCC) scoring system.\(^15\)

**Data quality assurance**

Data collectors were selected based on previous work experience at the oncology ward to reduce confusion during the data collection process. They were trained by the principal investigator regarding the data collection technique and process before the actual data collection was started. The data
abstraction tool was pretested using Cronbach’s alpha test in 5% (21 patient records) of the sample size at the UOGCSH oncology ward to assure the internal consistency of the tool so as to meet the objective of the study. Pretested patient records were not included in the final data analysis. The scale of reliability coefficient for NF was 72.25%, which was an acceptable internal consistency. An independent supervisor was closely following the data collection process and the completeness of the data was checked by the principal investigator daily.

**Statistical analysis**

The data were entered into a computer database using Epi-data version 4.6 and exported to STATA version 14.2 for better analysis. Continuous variables were presented as means (standard deviation). Categorical variables were presented as frequency and percentages. The logistics regression model was used to see the association between NF and independent variables. Multivariate logistic regression analysis was conducted for variables with a p-value <0.25 in bivariate analysis where p < 0.05 was considered statistically significant. The Hosmer–Lemeshow goodness-of-fit test for logistic regression was performed and the model was well fitted to NF (p = 0.42). In addition, time to recovery in NF between different regimes was compared using two-sample t-tests. The contingency coefficient test and variance inflation factors were used to check the presence of multicollinearity for categorical and continuous variables, respectively. The result of these tests showed that there was an insignificant correlation between variables.

**Operational definitions**

Absolute neutrophil count (ANC) (cells/mm$^3$) was defined as [total white blood cell (WBC) × (neutrophil % + %band)]/100. If the band is not available in the setup, it was set as 0 value. Neutropenia was defined as a reduction of ANC lower than 1500 cells, whereas NF means sustained body temperature of greater than 38°C for ≥1h in patients with ANC count <500 cells/mL or ANC decreased to <500 cells/mm$^3$ within 48 h. In this study, baseline ANC means ANC value before initiating the first cycle of chemotherapy, and chemotherapy dose delay is defined as a delay of planned

---

**Figure 1.** Sample size distribution of adult solid cancer patients at University of Gondar Comprehensive and Specialized Hospital from January 2017 to February 2021 (n=416).
Table 1. Socio-demographic characteristics of adult solid cancer patients at University of Gondar Comprehensive and Specialized Hospital from January 2017 to February 2021 (n=416).

| Variable        | Category          | Frequency, n | %  |
|-----------------|-------------------|--------------|----|
| Gender          | Male              | 94           | 23 |
|                 | Female            | 322          | 77 |
| Age             | <65               | 374          | 90 |
|                 | ⩾65               | 42           | 10 |
| Residence       | Urban             | 166          | 34 |
|                 | Rural             | 250          | 60 |
| Occupation      | Housewife         | 193          | 46 |
|                 | Governmental employer | 108      | 26 |
|                 | Farmer            | 73           | 18 |
|                 | Others*           | 42           | 10 |
| Marital status  | Single            | 19           | 5  |
|                 | Married           | 335          | 81 |
|                 | Divorced          | 30           | 7  |
|                 | Widowed           | 32           | 8  |
| BSA (m²)        | ⩽1.5 m²           | 142          | 34 |
|                 | >1.5 m²           | 274          | 66 |
| BMI (kg/m²)     | Underweight (<18.5) | 132     | 32 |
|                 | Normal (18.5–24.9) | 193      | 46 |
|                 | Overweight (25–29.9) | 69      | 17 |
|                 | Obesity (⩾30)     | 22           | 5  |

BSA: body surface area; BMI: body mass index.
*Merchant, student, person in spiritual schools.

chemotherapy for ⩾7 days.\textsuperscript{16} NF recovery is defined as patients who have normal body temperature and ANC greater than 500 cells/mm.\textsuperscript{3,14} For performance status, poor performance status is defined as an Eastern Cooperative Oncology Group (ECOG) (⩾2) and good performance status is ECOG (0–1).\textsuperscript{17}

Results

Socio-demographics and clinical characteristics of participants

A total of 416 patients were included in this study. The mean age of the patients was 51 ± 14 years. More than two-thirds of the patients were female (322 (77%)) (Table 1). More than half of the patients had good performance status (231 (56%)), and nearly, two-thirds of the patients (268 (64%)) had an advanced stage of cancer. Similarly, 155 (61%) patients had distant metastasis to the liver, lung, bone, and other sites of metastasis (Table 2).

Types of chemotherapeutic regimens for solid cancer treatment

A total of 416 patients took 416 courses of chemotherapy, 21 types of chemotherapy regimens, and 2708 chemotherapy cycles throughout their treatment regimens. The mean cycle of the treatment course was 6.3 ± 1.1. Adriamycin–cyclophosphamide with four cycles of paclitaxel (92 (22%)) followed by adriamycin–cyclophosphamide (86 (21%)) were the most commonly prescribed chemotherapy regimens (Table 3).

Incidence and distribution of NF

The study includes six common solid cancers in the hospital, where breast cancer was the most prevalent (152 (37%)). From a total of study participants, 259 (62%) patients developed neutropenia, and 54 (13%) patients (95% CI: 9.9–16.3) had NF. NF was most common in gestational trophoblastic disease and ovarian cancer (23% vs 22%), respectively (Table 4). The incidence of NF was more frequently encountered in the first cycle of chemotherapy and decreased subsequently through the eighth cycle (Figure 2).

Risk factors for NF

In the multivariate analysis advanced age, low baseline WBC, prolonged duration of neutropenia, and presence of two or more comorbidities were significantly associated with NF. Accordingly, patients aged ⩾65 had a risk to develop NF by odds of 3.5 to patients aged less than 65 years: adjusted odds ratio (AOR) 3.5 (95% CI: 1.2–10.3; \(p=0.022\)). Similarly, patients with lower baseline WBC had a high risk of NF by odds of 3.4 than patients with normal baseline WBC count: AOR 3.4 (95% CI: 1.1–10.7; \(p=0.033\)). Prolonged duration of neutropenia also increased the risk of NF by odds of 2.5 than patients with a shorter duration of
neutropenia: AOR 2.5 (95% CI: 1.2–5.3; p = 0.015). Patients having two or more comorbidities had a risk to develop NF by odds of 2.9 than patients who did not have comorbidities: AOR 2.9 (95% CI: 1.2–7.5; p = 0.021) (Table 5).

**Guideline adherence for NF prophylaxis and treatment**

According to NCCN guideline NF risk classifications, 92 (22%) patients were high risk, 28 (6.7%) patients were intermediate risk with a risk factor, 196 (47%) patients were an intermediate risk without risk factors, and 100 (24%) patients were unclassified risks. Of patients who need primary prophylaxis for the prevention of NF (92 + 28 = 120), 81 (68%) patients did not get primary prophylaxis. Regarding the time of prophylaxis, 27 (69%) of 39 patients got prophylaxis at an inappropriate time (Table 6). Management of NF was major with anti-bacterial. In addition to filgrastim, anti-viral and anti-fungal agents were used. Two-sample t-tests showed that the
addition of filgrastim to antibiotics significantly reduces NF recovery by 11 days (95% CI: 9.9–12; \( p = 0.0001 \)) as compared to antibiotic treatment only (Table 7). The majority of patients (49 (91%)) were treated with a combination of vancomycin. Of these combination regimens, vancomycin plus ceftazidime was most frequently (56%) prescribed. Based on IDSA guidelines, inappropriate prescribing of anti-bacterial, anti-fungal, and anti-viral agents was 30%, 71%, and 93% of prescriptions, respectively (Table 8).

### Discussion

In this study, the cumulative incidence of NF was 13% (95% CI: 9.9–16). The result was closely similar to other studies conducted previously in the world.\(^{18,19}\) However, the result was higher than previous studies done in Japan (6.9%) and Portugal (8%).\(^{20,21}\) This difference might be due to genetic variation; black populations had lower neutrophil count and leucocyte count relative to the white population.\(^{22}\) In addition, the patients in our study had a new cancer case and on first chemotherapy, the exposure would relatively be more sensitive to chemotherapy toxicity relative to recurrent cases.\(^ {20} \) However, the use of primary prophylaxis is not common in our setting. It was also higher than a study done in Nigeria (5.3%).\(^ {23} \) This variation might be due to the use of primary prophylactic G-CSF based on risk stratification is not common in our setup. NF was higher in breast cancer than other types of cancer. This result might be due to frequent use

---

**Table 3.** Regimen of chemotherapy administered among adult solid cancer patients from January 2017 to February 2021 at University of Gondar Comprehensive and Specialized Hospital (\( n = 416 \)).

| Regimens                              | Total number of patients (%) | Total number of cycles | Neutropenia, \( n \) (%) | NF, \( n \) (%) |
|---------------------------------------|------------------------------|------------------------|---------------------------|----------------|
| ACP                                   | 92 (22)                      | 736                    | 66 (16)                   | 9 (2)          |
| Cisplatin and paclitaxel              | 86 (21)                      | 516                    | 63 (15)                   | 13 (3)         |
| AC                                     | 59 (14)                      | 360                    | 50 (12)                   | 6 (1)          |
| FOLFOX                                 | 47 (11)                      | 256                    | 9 (2)                     | 5 (1)          |
| CAPOX                                  | 20 (4.8)                     | 120                    | 8 (2)                     | 1 (0.2)        |
| Cisplatin and gemcitabine             | 18 (4.3)                     | 102                    | 10 (2)                    | 2 (0.5)        |
| EMACO                                  | 15 (3.6)                     | 120                    | 15 (1)                    | 6 (1)          |
| Cisplatin, etoposide, and bleomycin   | 13 (3.2)                     | 78                     | 8 (2)                     | 3 (0.7)        |
| Paclitaxel and carboplatin            | 12 (2.9)                     | 72                     | 10 (2)                    | 5 (1)          |
| FOFLIRI                                | 11 (2.6)                     | 66                     | 3 (0.7)                   | 0 (0)          |
| Methotrexate                           | 11 (2.6)                     | 88                     | 2 (0.5)                   | 0 (0)          |
| Irinotecan and capecitabine           | 8 (1.9)                      | 48                     | 0 (0)                     | 0 (0)          |
| Carboplatin and gemcitabine           | 5 (1.2)                      | 30                     | 4 (0.9)                   | 3 (0.7)        |
| Cisplatin and SFU                     | 4 (1.0)                      | 24                     | 2 (0.5)                   | 1 (0.2)        |
| Cisplatin and etoposide               | 4 (0.9)                      | 24                     | 2 (0.5)                   | 0 (0)          |
| Cisplatin, adriamycin, and paclitaxel | 3 (0.7)                      | 18                     | 0 (0)                     | 0 (0)          |
| Cisplatin and adriamycin              | 3 (0.7)                      | 20                     | 3 (0.7)                   | 0 (0)          |
| Adriamycin, cyclophosphamide, and vincristine | 2 (0.5)      | 12                     | 2 (0.5)                   | 0 (0)          |
| Cyclophosphamide and cisplatin        | 1 (0.2)                      | 6                      | 1 (0.2)                   | 0 (0)          |
| Cisplatin, bleomycin, and SFU         | 1 (0.2)                      | 6                      | 0 (0)                     | 0 (0)          |
| SFU and leucovorin                    | 1 (0.2)                      | 6                      | 0 (0)                     | 0 (0)          |
| Total                                 | 416 (100)                    | 2708                   | 259 (62)                  | 54 (13)        |

AC: adriamycin–cyclophosphamide; ACP: adriamycin–cyclophosphamide followed by four cycles of paclitaxel; EMACO: etoposide, methotrexate, actinomycin, cyclophosphamide, and vincristine; FOFLIRI: folic acid–fluorouracil–irinotecan; FOLFOX: folic acid–fluorouracil–oxaliplatin; CAPOX: capecitabine oxaliplatin; SFU:5-fluorouracil.

**Table 4.** Distribution of chemotherapy-induced neutropenic fever among adult solid cancer patients by cancer type at University of Gondar Comprehensive and Specialized Hospital from January 2017 to February 2021 (\( n = 416 \)).

| Types of solid tumor       | Number of patients, \( n \) (%) | NF, \( n \) (%) |
|----------------------------|----------------------------------|----------------|
| Breast cancer              | 152 (37)                         | 15 (10)        |
| Colorectal cancer          | 87 (21)                          | 6 (7)          |
| Cervical cancer            | 67 (16)                          | 10 (15)        |
| Ovarian cancer             | 50 (12)                          | 11 (22)        |
| Lung cancer                | 34 (8)                           | 6 (18)         |
| GTN                        | 26 (6)                           | 6 (23)         |

GTN: gestational trophoblastic disease; NF: neutropenic fever.
Table 5. Multivariable logistic regression for associated factors of neutropenic fever incidence among adult solid cancer patients at University of Gondar Comprehensive and Specialized Hospital from January 2017 to February 2021 (n = 416).

| Factors                      | Categories          | NF (%) | COR (95% CI) | AOR (95% CI) | p-value |
|------------------------------|---------------------|--------|--------------|--------------|---------|
| Gender                       | Male                | 90 (25) |             |              |        |
|                              | Female              | 272 (75) | 4.1 (1.5–11.8) | 1.8 (0.5–6.6) | 0.39    |
| Age                          | <65                 | 332 (92) | 1             |              |        |
|                              | ⩾65                 | 30 (8)   | 3.2 (1.5–6.6) | 3.5 (1.2–10.3) | 0.022*  |
| Comorbidity number           | 0                   | 214 (59) | 1             |              |        |
|                              | 1                   | 99 (27)  | 2.6 (1.3–5.4) | 1.4 (0.6–3.4) | 0.44    |
|                              | ⩾2                  | 49 (14)  | 6.1 (2.9–12.7) | 2.9 (1.2–7.5) | 0.02*   |
| Stage                        | Stages I and II     | 144 (40) | 1             |              |        |
|                              | Stages III and IV   | 218 (60) | 8.3 (2.9–23.4) | 1.9 (0.6–6.4) | 0.31    |
| ECOG-PS                      | 0–II                | 213 (59) | 1             |              |        |
|                              | III–IV              | 149 (41) | 2.9 (1.6–5.2) | 0.7 (0.3–1.6) | 0.41    |
| BMI                          | Normal              | 172 (48) | 1             |              |        |
|                              | Underweight         | 106 (29) | 2 (1.1–3.8)   | 0.7 (0.3–1.6) | 0.39    |
|                              | Overweight          | 65 (18)  | 0.5 (0.2–1.5) | 0.7 (0.2–2.6) | 0.59    |
|                              | Obesity             | 19 (5)   | 1.3 (0.4–4.7) | 0.6 (0.1–3.3) | 0.58    |
| WBC (cells/mm³)              | ⩾3500               | 208 (58) | 6 (11)        |              |        |
|                              | <3500               | 154 (60) | 48 (89)       | 10.8 (4.5–25) | 3.4 (1.1–10.7) | 0.033* |
| Albumin                      | ⩾3.5                | 217 (59) | 17 (32)       |              |        |
|                              | <3.5                | 145 (40) | 37 (66)       | 3.3 (1.8–6.1) | 1.2 (0.5–2.7) | 0.66    |
| Paclitaxel–carboplatin       | No                  | 355 (98) | 49 (91)       |              |        |
|                              | Yes                 | 7 (2)    | 5 (9)         | 5.2 (1.6–16.9) | 2.8 (0.5–15.4) | 0.24    |
| Treatment modalities of      | Chemotherapy only   | 53 (15)  | 6 (11)        |              |        |
| cancer                       | Chemotherapy + surgery | 207 (57) | 14 (26)      | 0.6 (0.2–1.6) | 0.4 (0.1–3.3) | 0.28    |
|                              | Chemotherapy + radiotherapy | 20 (6)  | 1 (2)        | 0.4 (0.1–3.9) | 0.2 (0.01–3.3) | 0.25    |
|                              | Chemotherapy radiotherapy + surgery | 82 (23) | 33 (61) | 3.6 (1.4–9.0) | 1.6 (0.5–5.4) | 0.46    |
| LDH                          | Normal              | 143 (40) | 4 (7)         |              |        |
|                              | Elevated            | 219 (61) | 50 (93)       | 8.2 (2.9–23.1) | 1.3 (0.3–4.8) | 0.74    |
| ANC count (10³ cells/mm³)    | ⩾2.47 ± 0.760 ± 0.76 | 153 (42) | 6 (11)       |              |        |
| (mean ± SD)                  | <2.47 ± 0.760 ± 0.76 | 209 (58) | 48 (89)      | 5.9 (2.4–14.0) | 1.6 (0.5–5.3) | 0.41    |
| Duration neutropenia         | ⩽7                  | 132 (37) | 23 (43)       |              |        |
| resolution (days)            | >7                  | 73 (20)  | 31 (57)       | 2.4 (1.3–4.5) | 2.5 (1.2–5.3) | 0.015*  |

NF: neutropenic fever; AOR: adjusted odds ratio; COR: crude odds ratio; CI: confidence interval; ECOG-PS: eastern cooperative oncology group performance status; BMI: body mass index; LDH: lactate dehydrogenase; ANC: absolute neutrophil count; WBC: white blood cell.

*Significance (p < 0.05).
of high-risk chemotherapy regimens—doxorubicin, cyclophosphamide, and taxane-based regimen which has a high bone marrow suppression adverse effect. The incidence of NF episodes was higher in the first (15%) and second cycles (13%) and decreased in subsequent cycles. The finding was consistent with previous studies done in the United States, Europe, and Denmark. This might be because patients had lower tolerability levels at the onset of chemotherapy. The mean duration of NF was 48 days. This was longer than a study conducted in the United States (11 days) and Belgium (6 days). This difference might be due to a lack of frequent monitoring of complete blood count as per standards in our setting.

Older age (≥65 years) was a risk factor for chemotherapy-induced NF. This result was supported by other studies carried out in Europe, the United States, Korea, Australia, and Japan. This might be due to immune senescence, a phenomenon which is a gradual deterioration of the immune system with aging. In addition, this group of patients could have reduced bone marrow, liver, and renal functions and is more susceptible to chemotherapy-induced complications.

The prolonged duration of neutropenia was significantly associated with the incidence of NF. This result was in line with studies conducted in the United States and Korea. This might be because a longer period of myelosuppression will render patients prone to infections. Similarly, the presence of two or more comorbidities was significantly associated with NF. This could be due to several underlying pathologic mechanisms, including defective bone marrow functions, impaired phagocyte systems, and altered barrier function which might be increase access of microorganisms into the body.

Different studies showed that cancer patients have a high risk for tuberculosis (TB) and also there are a high prevalence of human immune deficiency virus (HIV) infection. The risk of TB in cancer patients is due to immunosuppression caused by chemotherapy and local anatomical alterations in the lungs caused by primary lung cancer or metastasis. HIV infection itself is a risk factor for malignancy and a cause of cancer-related death. Particular sub-Saharan Africa is by far the most affected region of the world by the HIV pandemic, with 25.8 million people living with HIV (69.9% of the total). A review conducted in sub-Sahara Africa showed that the incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and squamous cell lesion was increased 4, 4, and 21.9 times among HIV-positive patients. This strong association between cancer and HIV infection was not supported by our findings. This variation might be because of the poor screening habits of participants in our study. In addition, we used a retrospective follow-up study; therefore, important cancer comorbid conditions might have been missed. In the future, it could be interesting to investigate the

| Table 6. NCCN guideline adherence of neutropenic fever prophylaxis among adult solid cancer patients at University of Gondar Comprehensive and Specialized Hospital from January 2017 to February 2021 (n=416). |
|-----------------|-----------------|-----------------|
| Patient status  | Frequency, n    | %               |
| High risk       | 92              | 22              |
| Intermediate risk with risk factors | 28 | 7 |
| Intermediate risk without risk factors | 196 | 47 |
| Unclassified FN risk | 100 | 24 |
| Total           | 416             | 100             |
| The total number of patients who need primary prophylaxis | 120 | 100 |
| Patient got primary prophylaxis | 39 | 33 |
| Total patients did not get appropriate NF prophylaxis | 81 | 68 |
| Prophylaxis administered after 24–72h of chemotherapy administration | 12 | 31 |
| Prophylaxis administered before chemotherapy administration | 10 | 26 |
| Prophylaxis administered simultaneously with chemotherapy administration | 17 | 44 |
| Total patients did not get prophylaxis with the inappropriate time of administration | 27 | 69 |

FN: neutropenic fever.

| Table 7. Filgrastim use comparison for neutropenic fever among adult solid cancer patients at University of Gondar Comprehensive and Specialized Hospital from January 2017 to February 2021 (n=416). |
|-----------------|-----------------|-----------------|
| Type of interventions | n (%) | Meantime neutropenia recovery(days) |
| NF management | Two-sample t-test for neutropenic fever recovery time (days) | |
| Types of NF management | n (%) | |
| Antibiotics plus filgrastim | 38 (70) | 11 (95% CI: 9.9–12.2; p=0.0001) |
| Antibiotics only | 16 (30) | 30 |

NF: Neutropenic fever.
level of association between cancer with TB, and HIV in different health care institutions with a large sample size.

Of the total study participants, 68% of patients received prophylaxis. However, only 31% of participants received appropriate prophylaxis as per NCCN recommendations time for the prevention of NF, which stated patients should receive G-CSF therapy within 24–72 h of post-chemotherapy.42 This report was supported by other different studies conducted in the world.14,43,44 This guideline non-adherence might be due to inadequate training and experience of prescribers and, a lack of standard treatment protocol in our setting.45

More than two-thirds of NF patients (70%) were treated with antibiotics plus filgrastim. The result of our study was in agreement with the American Society of Clinical Oncology (ASCO) recommendations.46 The finding of our study showed that adjuvant use of filgrastim to NF significantly reduced the time of neutrophil recovery. The finding was supported by a previous observational study in Pakistan and India.47,48 This might be because the use of filgrastim accelerates the production and circulating of neutrophils by reducing the transient time from stem cells to mature neutrophils.49 In this study, the majority (95%) of the patients were treated with combined antibiotics and 30% of prescription was inappropriate.

Vancomycin-based combinations were the most frequently prescribed regimen in this study (91%). This finding was consistent with a study conducted at Black Lion Specialized Hospital, Ethiopia.50 However, 33% of vancomycin was inappropriately indicated based on criteria set by the IDSA 2010 guideline. Studies conducted in United States and Korea showed that the addition of vancomycin had no significant benefit on reduction of mortality; rather, it increased the risk of antibiotic resistance and nephrotoxicity.51,52 In addition, this study found that the majority (82%) of patients received anti-fungals, but 71% of them inappropriately. The finding was supported by studies conducted in France, Spain, and California.53–55 This guideline non-adherence might be due to poor practice of definitive therapy due to the lack of specific microorganism identification techniques in our setting. In our study, 50% of patients received anti-viral agents. However, the majority of the patients

| Antibiotics type | High risk, n (%) | Low risk, n (%) | Total, n (%) | Inappropriate indication, n (%) |
|------------------|-----------------|----------------|--------------|--------------------------------|
| Antibacterial    |                 |                |              |                                |
| Ceftazidime plus vancomycin | 22 (41) | 8 (15) | 30 (56) | 8 (15) |
| Cefepime plus vancomycin | 11 (21) | 4 (7) | 15 (28) | 4 (7) |
| Meropenem plus vancomycin | 3 (6) | 1 (2) | 4 (7) | 1 (2) |
| Metronidazole plus ceftriaxone | 2 (4) | 0 (0) | 2 (4) | 2 (4) |
| Cefepime | 1 (2) | 0 (0) | 1 (2) | 0 (0) |
| Ceftazidime | 1 (2) | 1 (2) | 2 (4) | 1 (2) |
| Total | 40 (74) | 14 (26) | 54 (100) | 16 (20) |

The overall distribution of monotherapy and combination therapy

| Antibiotics type | High risk, n (%) | Low risk, n (%) | Total, n (%) | Inappropriate indication, n (%) |
|------------------|-----------------|----------------|--------------|--------------------------------|
| Monotherapy    |                 |                |              |                                |
| Combined therapy with vancomycin | 36 (67) | 13 (24) | 49 (91) | 13 (24) |
| Combined therapy with other antibiotics | 2 (4) | 0 (0) | 2 (4) | 2 (4) |
| Total | 40 (74) | 14 (26) | 54 (100) | 16 (30) |
| Total inappropriate vancomycin addition | 10 (20) | 6 (12) | 16 (33) | 16 (33) |

Anti-viral and anti-fungal addition

| Time of addition | Frequency, n | % | Inappropriate indication, n (%) |
|------------------|--------------|---|--------------------------------|
| Anti-fungal      |              |   |                                |
| Anti-fungal initially with antibiotics | 31 | 71 | 31 (71) |
| Anti-fungal after 4 days of antibiotics when fever is persists | 13 | 30 | 0 (0) |
| Total | 44 | 100 | 31 (71) |
| Anti-viral       |              |   |                                |
| Anti-viral initially with antibiotics | 21 | 78 | 21 (78) |
| Anti-viral after 4 days with anti-fungal | 4 | 15 | 4 (15) |
| Anti-viral after fever persists with clinical evidence | 2 | 7 | 0 (0) |
| Total | 27 | 100 | 25 (93) |
(93%) took anti-viral without evidence of viral infection, which was contradicted IDSA guidelines.14

Limitation of the study
This study has several limitations. This study was conducted in one hospital setting; the result may not be generalized to whole health care centers in Ethiopia. As we used a retrospective follow-up study, the necessary data such as chemotherapy dose reduction, previous antibiotics use, and duration of therapy might have been missed. Determinants of neutropenic fever might be affected by imprecision, since the confidence intervals of the AOR were large, probably due to the small number of events for each outcome. Similarly, continuous variables in this study were dichotomized, and also the high number of independent variables was included in the multivariable model which might reduce the statistical power and result in an over-fitted model, respectively. In addition, the incidence of NF might be affected by the quality of life, and nutritional status, which were unable to address in this study. Despite these limitations, this study gives new insights into the incidence, guideline adherence to management practice, and predictors of NF among adult solid cancer patients, which could serve as a source of direction by identifying areas for intervention.

Conclusion
This study showed that the incidence of NF among solid cancer was high. It occurs most frequently during the first and second cycles of chemotherapy than in subsequent cycles with a mean duration of 38 days. Advanced age, low baseline WBC, prolonged duration of neutropenia, and the presence of two or more comorbidities were independent predictors of NF. More than one-half of solid cancer patients (53%) were treated with surgery and chemotherapy. According to the NCCN guideline, 68% of patients did not get appropriate primary prophylaxis. NF was mainly managed by a combination of antibiotics. The addition of filgrastim to antibiotics significantly reduced neutropenia fever recovery time by 11 days. The rate of IDSA guideline adherence during treatment of NF was poor. Among prescribed anti-bacterial, anti-fungal, and anti-viral agents, 30%, 71%, and 93% of prescriptions, respectively, were inappropriate based on this guideline. Predicting and screening high-risk NF has great clinical significance. This may help to monitor and manage NF which improves the outcome of chemotherapy. Risk factors of NF are multidimensional and health care professionals should be aware of these risk factors, and maximum effort is important to reduce the risk of NF in the early course of chemotherapy. In addition, more research considering tumor biomarkers and prospective follow-up study are important to assess the overall condition. The Ministry of health should also prepare a standardized and updated local guideline for the management of NF for a better outcome for cancer patients.

Acknowledgements
The authors thank participants, the University of Gondar, and data record staff members of the University of Gondar

Author contributions
S. A. W. had an important contribution to the conception and design of this study; S.A., E.M.D., S.T.A., M.K., and B.K. have contributed to statistical analysis and interpretation, and also participated during manuscript preparation, and agreed and gave approval to the manuscript to be submitted and published in this journal. They agree to be accountable for all aspects of the work.

Availability of data and materials
The data sets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical considerations
Ethical approval for this study was obtained from the Ethical Clearance Committee of the Department of Clinical Pharmacy, the School of Pharmacy, the University of Gondar (APPROVAL NUMBER/ID SOPs/133/2021). Informed consent was waived since the study was conducted retrospectively, and also, it was difficult to get the study participants directly. Confidentiality of the patients was maintained by ensuring the data obtained from study participants were used only for research purposes. In addition, the information collected was not directly linked to the respective participants; in the way that the names of patients were not used. Codes were used as an identifier.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the School of Pharmacy, College of Medicine and Health Sciences, University of Gondar. The University has no role in designing, conducting, and reporting the study

Informed consent
Informed consent was waived since the study was conducted retrospectively, and also, it was difficult to get the study participants directly.

ORCID iDs
Ephrem Mebratu Dagnew https://orcid.org/0000-0003-1117-2636
Mekdes Kiflu https://orcid.org/0000-0001-5387-8253
Bekalu Kebede https://orcid.org/0000-0001-9758-4265

Supplemental material
Supplemental material for this article is available online.

References
1. Admasu DK. Federal Ministry of health National Cancer Control Plan, 2015, https://www.iccp-portal.org/sites/default/files/plans/NCCP%20Ethiopia%20Final%20261015.pdf
2. Sisay F, Abebe A, Sebsibie G, et al. Treatment outcome of oncologic patients treated in the emergency department at black lion specialized hospital, Ethiopia. *Maj Women’s Health* 2018; 7: 125–127.

3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008. *GLOBOCAN 2008. Int J Cancer* 2010; 127(12): 2893–2917.

4. Wassie M, Aemro A and Fentie B. Prevalence and associated factors of baseline anemia among cervical cancer patients in Tikur Anbessa Specialized Hospital. *BMC Women’s Health* 2021; 21: 36.

5. Poole EM, Tissing WJ, Kamps WA, et al. Risk assessment in fever and neutropenia in children with cancer. *Crit Rev Oncol Hematol* 2009; 72(1): 45–55.

6. Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. *Cancer* 2010; 116(23): 5555–5563.

7. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. *Cochrane Database Syst Rev* 2012; 2012(1): CD004386.

8. Klasky J, de Maurois J, Rolston K, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. *Ann Oncol* 2016; 27(5): 111–118.

9. Gulleen EA, Adams SV, Chang BH, et al. Factors and outcomes related to the use of guideline-recommended antibiotics in patients with neutropenic fever at the Uganda Cancer Institute. *Open Forum Infect Dis* 2021; 8(7): 307–329.

10. Abbas Z and Rehman S. An overview of cancer treatment guidelines. *Clin Infect Dis* 2011; 52(4): e56–e93.

11. Badr M, Hassan T, Sakr H, et al. Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: risks and consequences. *Mol Clin Oncol* 2016; 5(3): 300–306.

12. Rosa RG and Goldani LZ. A cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. *Antimicrob Agents Chemother* 2014; 58(7): 3799–3803.

13. Osterborg A. Common terminology criteria for adverse events (CTCAE). *CTCAE 2010; 24(12): 1–5."

14. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2011; 52(4): e56–e93.

15. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. *J Clin Oncol* 2018; 36(14): 1443–1453.

16. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. *J Clin Oncol* 2014; 25(21): 3158–3167.

17. Okera M, Chan S, Demede U, et al. A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG / NCEPOD findings. *Br J Cancer* 2011; 104: 407–412.

18. Wilson-royalty M, Lawless G, Palmer C, et al. Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. *J Oncol Pharm Pract* 2001; 7: 141–147.

19. Schwenkglenks M, Pettengell R, Jackisch C, et al. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. *Support Care Cancer* 2011; 19(4): 483–490.

20. Hashiguchi Y, Kasai M, Fukuda T, et al. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. *Anticancer Drugs* 2015; 26(10): 1054–1060.

21. Moreira-Pinto J, Leao I, Palmela C, et al. Febrile neutropenia in patients with solid tumors undergoing intravenous chemotherapy. *Oncol Res Treat* 2020; 43(11): 605–612.

22. Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. *Ann Intern Med* 2004; 146(19): 486–492.

23. Salako O, Okunade KS, Adeniji AA, et al. Chemotherapy-induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria. *Eacancermedicalscience* 2021; 15: 1188.

24. Crawford J, Wolff D, Culakova E, et al. First-cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: results from a prospective nationwide study. *J Support Oncol* 2005; 3(2): 52–327.

25. Morrison VA, Weller EA, Habermann TM, et al. Patterns of Growth Factor Usage and Febrile Neutropenia Among Older Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma Treated with CHOP or R-CHOP: the Intergroup Experience (CALGB 9793; ECOG-SWOG 4494). *Leuk Lymphoma* 2017; 58(8): 1814–1822.

26. Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. *Br J Haematol* 2009; 144(5): 677–685.

27. Aagaard T, Reekie J, Roen A, et al. Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2–6 in patients with solid cancers: the CSRFEHC score. *Int J Cancer* 2020; 146(2): 321–328.

28. Lalami Y, Paesmans M, Muanza F, et al. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. *Ann Oncol* 2006; 17: 507–514.

29. Laskey RA, Pioniewierski MS, Lopez MA, et al. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. *Gynecol Oncol* 2012; 125(3): 625–630.

30. Kim YR, Kim SJ, Park Y, et al. Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis. *Korean J Intern Med* 2021; 36(5): 1181–1189.

31. Salar A, Haioun C, Rossi FG, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. *Leuk Res* 2012; 36(5): 548–553.
32. Okunaka M, Kano D, Matsui R, et al. Comprehensive analysis of chemotherapeutic agents that induce infectious neutropenia. *Pharmaceuticals* 2021; 14(7): 1–12.

33. Lyman GH, Abella E and Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. *Crit Rev Oncol Hematol* 2014; 90(3): 190–199.

34. Shrestha S, Shrestha S and Khanal S. Polypharmacy in elderly cancer patients: challenges and the way clinical pharmacists can contribute in resource-limited settings. *Aging Med (Milton)* 2019; 2(1): 42–49.

35. Li Y, Klippel Z, Shih X, et al. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with non-myeloid malignancies. *Support Care Cancer* 2016; 24(10): 4377–4383.

36. Chao C, Page JH, Yang SJ, et al. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. *Ann Oncol* 2014; 25(9): 1821–1829.

37. Elhadi M, Khaled A and Msherghi A. Infectious diseases as a cause of death among cancer patients: trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database. *Infect Agent Cancer* 2021; 16(1): 72.

38. Dobler CC, Cheung K, Nguyen J, et al. Risk of tuberculosis in patients with solid cancers and hematological malignancies: a systematic review and meta-analysis. *Eur Resp J* 2017; 50(2): 3–10.

39. Nanthanangkul S, Promthet S, Suwanrungruang K, et al. Incidence of and risk factors for tuberculosis among cancer patients in an endemic area: a Regional Cohort Study. *APJCP* 2020; 21(9): 2715–2730.

40. The Joint United Nations Programmed on HIV/AIDS (UNAIDS). *Fact sheet: 2014 statistics.* Geneva: WHO, 2014, pp. 3–9.

41. Sasco AJ, Jaquet A, Boidin E, et al. The challenge of AIDS-related malignancies in sub-Saharan Africa. *PLoS ONE* 2010; 5(1): 2–7.

42. Becker PS, Griffiths EA, Alwan LM, et al. Hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines. *JNCCN J Natl Compr Canc Netw* 2020; 18(1): 12–22.

43. Wang L, Barron R, Baser O, et al. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration. *Value Health* 2014; 17(6): 739–743.

44. Özdemir ZC. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. *JAMA Intern Med* 2015; 173(7): 559–568.

45. Barnes G, Pathak A and Schwartzberg L. G-CSF utilization rate and prescribing patterns in the United States: associations between physician and patient factors and GCSF use. *Cancer Med* 2014; 3(6): 1477–1484.

46. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *J Clin Oncol* 2006; 24(19): 3187–3205.

47. Advani SH, Achreckar S, Thomas D, et al. Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia. *Indian J Med Paediatr Oncol* 2010; 31(3): 79–82.

48. Osmani AH, Ansari TZ, Masood N, et al. Outcome of febrile neutropenic patients on granulocyte-colony-stimulating factor in a tertiary care hospital. *Asian Pac J Cancer Prev* 2012; 13(6): 2523–2526.

49. Rapoport BL. Management of the cancer patient with infection and neutropenia. *JSONC Med* 2014; 3(6): 1477–1484.

50. Girma BT. *Assessment of the management of neutropenic fever in adult patients with hematologic malignancies at Tikur Anbessa Specialized Hospital.* Master’s Thesis, Addis Ababa University, May 2017.

51. Vardakas KZ, Samonis G, Chrysanthopoulou SA, et al. Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. *Lancet Infect Dis* 2005; 5(7): 431–439.

52. Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. *Korean J Intern Med* 2011; 26(2): 220–252.

53. Zafrani L and Azoulay E. How to treat severe infections in critically ill neutropenic patients? *BMC Infect Dis* 2014; 14: 512.

54. Villafuerte-Gutierrez P, Villalon L, Losa JE, et al. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. *Adv Hematol* 2014; 52: 5–9.

55. Pizzo PA. Management of patients with fever and neutropenia through the arc of time. *Ann Intern Med* 2019; 170(6): 389–397.